Drug formulary modernization involves the enhancement and refinement of the management and utilization of drug formularies within healthcare systems or organizations. Our aim is to offer a comprehensive resource for healthcare experts, policymakers, researchers, and the general public. Through an assortment of research papers, reports, and drug class reviews, our objective is to provide you with the information necessary to navigate the intricate terrain of drug policy.
The ODPRN is not currently conducting drug class reviews at this time.
The ODPRN has completed a total of 12 drug class reviews since 2013. These reviews were based on an innovative framework that incorporated systematic reviews and network meta-analysis, economic modeling, real-world prescribing and adherence, qualitative analysis of patient and clinician perspectives, and an environmental scan of listing across Canada. Research findings were synthesized to make recommendations to the Ontario Ministry of Health and Long-Term Care regarding public drug reimbursement policies.
Find out about our drug class review process.
Deliverables
All completed reviews contain the following:
The ODPRN has completed a total of 12 drug class reviews since 2013. These reviews were based on an innovative framework that incorporated systematic reviews and network meta-analysis, economic modeling, real-world prescribing and adherence, qualitative analysis of patient and clinician perspectives, and an environmental scan of listing across Canada. Research findings were synthesized to make recommendations to the Ontario Ministry of Health and Long-Term Care regarding public drug reimbursement policies.
Find out about our drug class review process.
Deliverables
All completed reviews contain the following:
- The final research plan: A detailed description of how each study was conducted within the drug class review
- All final research reports: Includes a consolidated report of all research findings and proposed reimbursement options
- Resources: Summaries and infographics to facilitate understanding of our drug class review findings
Self-monitoring of blood glucose for patients with diabetes on insulin therapy is considered an essential part of management. However, the clinical benefit of regular testing for most patients with type 2 diabetes not using insulin, has been questioned, with concerns that frequent testing could even lead to decreased quality of life.
The ODPRN has conducted multiple studies on blood glucose test strips (BGTS) primarily focusing on the impact of BGTS quantity limits on utilization, costs and patient outcomes.
*UPDATE THIS INFORMATION* The ODPRN has conducted pivotal research on biologic medications, focusing on their utilization, safety, effectiveness, and cost within Ontario.
*UPDATE THIS INFORMATION* The ODPRN analyzes the utilization, safety, effectiveness, and economic impact of high-cost drugs in Ontario. This work informs policymakers on managing high-cost medications to ensure optimal patient outcomes and financial sustainability. ODPRN's evaluations of prescribing trends, cost-effectiveness, and the healthcare system's burden have shaped evidence-based drug policies and improved healthcare delivery in Ontario.